Fosun International’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Fosun International’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-188,673	Closed	-$2.97M	–	315
2019 Q2	$2.97M	Hold	188,673	–	–	0.2%	79
2019 Q1	$2.67M	Buy	188,673 +74,735	+66%	+$859K	0.17%	80
2018 Q4	$1.15M	Buy	+113,938	New	+$1.5M	0.07%	122

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fosun International's DRNA Position: Q3 2019 in Review

Fosun International sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2019, closing a stake of 188,673 shares — an estimated $2.97M sold.

Fosun International first reported a position in DRNA in Q4 2018 and held it in 3 quarters. The position peaked at $2.97M in Q2 2019. 112 funds tracked by Wall St. Rank hold DRNA as of Q3 2019.

Fosun International reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Fosun International sold 188,673 Dicerna Pharmaceuticals, Inc. shares in Q3 2019, an estimated $2.97M.
Fosun International first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
Fosun International's Dicerna Pharmaceuticals, Inc. position peaked at $2.97M in Q2 2019.
112 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.